Compare Incyte Corporation (INCY) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marqeta Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Marqeta Inc trades at $18.11 (market cap $1.82B). The key difference: Incyte Corporation is far larger — about 12.6× Marqeta Inc's market cap, and Incyte Corporation is more actively traded (1,927,029 versus 1,126,466). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Marqeta Inc for 44 Days on average.
| INCY | MQ | |
|---|---|---|
Market Cap | $22.85B | $1.82B |
Volume | 1,927,029 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $129.93 | $20.32 |
52-Week Low | $83.80 | $15.04 |
Typical Hold Time | 33 Days | 44 Days |
Enterprise Value | $18.35B | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Marqeta (MQ) trades at $17.44, up 2.23% today, showing strong momentum after beating earnings expectations for three consecutive quarters. The stock displays a bullish technical outlook with positive moving average signals, though valuation metrics remain elevated with a P/E of 193.83. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight ongoing business expansion despite mixed analyst sentiment.
MQ presents a high-risk, high-reward opportunity with improving fundamentals but premium valuation. Revenue growth has recovered from 2024 lows, and cash flow turned positive in 2025. However, the stock trades above most analyst targets, and contract renewals in Q3 2026 create near-term uncertainty. Investors should weigh growth potential against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
